Overview

Open-label Trial of SUBA™-Itraconazole (SUBA-Cap) in Subjects With Basal Cell Carcinoma Nevus Syndrome (BCCNS)

Status:
Completed
Trial end date:
2019-03-01
Target enrollment:
Participant gender:
Summary
The study will assess the safety and efficacy of SUBA-Cap in subjects with Basal Cell Carcinoma Nevus Syndrome.
Phase:
Phase 2
Details
Lead Sponsor:
HedgePath Pharmaceuticals, Inc.
Treatments:
Hydroxyitraconazole
Itraconazole